-
公开(公告)号：EP3600295A1
公开(公告)日：2020-02-05
申请号：EP18776871.8
申请日：2018-03-29
申请人： The George Washington University, A Congressionally Chartered Not-For-Profit Corporation , The Board of Trustees of the University of Illinois
IPC分类号： A61K31/42 , A61K31/422 , A61K45/06
-
2.发明授权3-BENZOFURANYL-4-INDOLYL-MALEIMIDES AS POTENT GSK-3 INHIBITORS FOR NEURODEGENERATIVE DISORDERS 有权GS-3的神经变性疾病的3-苯并呋喃基-4-吲哚基 - 马来酰亚胺作为有效抑制剂
公开(公告)号：EP2125683B1
公开(公告)日：2013-10-23
申请号：EP07865893.7
申请日：2007-12-19
IPC分类号： C07C49/00 , C07D249/00 , C07D285/00 , C07D405/14 , A61K31/404 , A61P25/28
CPC分类号： C07D405/14
-
3.发明公开3-BENZOFURANYL-4-INDOLYL MALEIMIDES AS POTENT GSK3 INHIBITORS FOR NEUROGENERATIVE DISORDERS 有权GS-3的神经变性疾病的3-苯并呋喃基-4-吲哚基 - 马来酰亚胺作为有效抑制剂
公开(公告)号：EP2125683A1
公开(公告)日：2009-12-02
申请号：EP07865893.7
申请日：2007-12-19
IPC分类号： C07C49/00 , C07D249/00 , C07D285/00
CPC分类号： C07D405/14
摘要： Compounds of formula (I): and pharmaceutically acceptable salts, esters and solvates thereof, where variables are defined in the specification, useful generally as inhibitors of protein kinases and particularly useful for inhibition of GSK-3. Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy, motor neuron disease, cranial or spinal trauma, neurodegenerative disorders, including multiple sclerosis (MS), Alzheimer's disease, Fragile X syndrome, autism, Huntington's disease, Parkinson's
-
-
搜索结果
3 条记录 (耗时 0.023 秒)
